Patents by Inventor Isabel DEVESA GINER

Isabel DEVESA GINER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11634458
    Abstract: The present invention relates to a family of peptides which are able to interfere in the formation of complex Munc18-Syntaxin-1 and, hence, are useful in the prevention and/or treatment of neuronal exocytosis and/or muscle contractility disorders; and to prevent, reduce and/or eliminate skin aging and/or expression signs.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: April 25, 2023
    Assignee: LIPOTRUE, S.L.
    Inventors: Ariadna Grau-Campistany, Silvia Pastor, Patricia Carulla, Juan Carlos Escudero, Julia A. Boras, Isabel Devesa Giner, Gregorio Fernandez Ballester
  • Publication number: 20220296489
    Abstract: The invention relates to peptides capable of inhibiting neuronal exocytosis and to products comprising such peptides, in particular pharmaceutical and cosmetic products useful for ameliorating skin conditions, disorders and/or diseases mediated by neuronal exocytosis, such as wrinkles, excessive perspiration, pruritus, cutaneous inflammation, dermatitis, atopia, psoriasis, vascular hyperreactivity, rosacea, acne, hair growth, wound healing, calluses, warts, or sensitive skin conditions, such as ulcers and lesions on the skin.
    Type: Application
    Filed: June 11, 2019
    Publication date: September 22, 2022
    Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. S.p.A.
    Inventors: Francesca MANCINI, Isabel DEVESA GINER, Antonio FERRER MONTIEL, Gregorio FERNANDEZ BALLESTER, Giorgina MANGANO, Cristina BARTELLA
  • Publication number: 20220142898
    Abstract: Peptides able to inhibit the muscarinic receptor M3 activity and to products comprising such peptides, in particular pharmaceutical and cosmetic products useful for ameliorating skin conditions mediated by the muscarinic receptor M3 activity, such as excessive perspiration, inflammation, sebum production, and cell adhesion, motility, growth, differentiation and proliferation.
    Type: Application
    Filed: June 11, 2019
    Publication date: May 12, 2022
    Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. S.p.A.
    Inventors: Francesca MANCINI, Isabel DEVESA GINER, Antonio FERRER MONTIEL, Gregorio FERNANDEZ BALLESTER, Giorgina MANGANO, Cristina BARTELLA
  • Patent number: 11274073
    Abstract: The present invention relates to TRPV1 modulator compounds of formula (I) or their pharmaceutically, veterinary or cosmetically acceptable salts, or their stereoisomers or mixtures thereof, wherein m is an integer selected from 1 to 3; R1, R2, R6 and R6? are independently selected from H, (C1-C8)alkyl, unsaturated (C2-C8)hydrocarbon, and (C3-C6)cycloalkyl, being these groups optionally substituted; R3 is hydrogen or halogen; R4 is selected from H, (C1-C8)alkyl, unsaturated (C2-C8)hydrocarbon, (C3-C6)cycloalkyl, (C6-C12)aryl, and (C5-C12)heteroaryl, being these groups optionally substituted; and R5 is selected from (C3-C28)alkyl, unsaturated (C3-C28)hydrocarbon, (C6-C12)aryl, and (C5-C12)heteroaryl, being these groups optionally substituted. It also relates to a process for their preparation, to pharmaceutical, veterinary or cosmetic compositions containing them, and to their pharmaceutical, veterinary and cosmetic applications.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: March 15, 2022
    Assignee: ANTALGENICS, S.L.
    Inventors: Isabel Devesa Giner, Armando Genazzani, Tracey Pirali, Asia Fernandez Carvajal, Antonio Vicente Ferrer Montiel
  • Publication number: 20210032287
    Abstract: The present invention relates to a family of peptides which are able to interfere in the formation of complex Munc18-Syntaxin-1 and, hence, are useful in the prevention and/or treatment of neuronal exocytosis and/or muscle contractility disorders; and to prevent, reduce and/or eliminate skin aging and/or expression signs.
    Type: Application
    Filed: February 22, 2019
    Publication date: February 4, 2021
    Inventors: Ariadna GRAU-CAMPISTANY, Silvia PASTOR, Patricia CARULLA, Juan Carlos ESCUDERO, Julia A. BORAS, Isabel DEVESA GINER, Gregorio FERNANDEZ BALLESTER
  • Publication number: 20200199063
    Abstract: The present invention relates to TRPV1 modulator compounds of formula (I) or their pharmaceutically, veterinary or cosmetically acceptable salts, or their stereoisomers or mixtures thereof, wherein m is an integer selected from 1 to 3; R1, R2, R6 and R6? are independently selected from H, (C1-C8)alkyl, unsaturated (C2-C8)hydrocarbon, and (C3-C6)cycloalkyl, being these groups optionally substituted; R3 is hydrogen or halogen; R4 is selected from H, (C1-C8)alkyl, unsaturated (C2-C8)hydrocarbon, (C3-C6)cycloalkyl, (C6-C12)aryl, and (C5-C12)heteroaryl, being these groups optionally substituted; and R5 is selected from (C3-C28)alkyl, unsaturated (C3-C28)hydrocarbon, (C6-C12)aryl, and (C5-C12)heteroaryl, being these groups optionally substituted. It also relates to a process for their preparation, to pharmaceutical, veterinary or cosmetic compositions containing them, and to their pharmaceutical, veterinary and cosmetic applications.
    Type: Application
    Filed: May 10, 2018
    Publication date: June 25, 2020
    Applicant: ANTALGENICS, S.L.
    Inventors: Isabel DEVESA GINER, Armando Genazzani, Tracey Pirali, Asia Fernandez Carvajal, Antonio Vicente Ferrer Montiel